5 questions with Elissa Cote, Director of Strategy and Business Development, Mallinckrodt PharmaceuticalsBioBuzz
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital area to share a little bit about themselves, their work, and maybe something completely unrelated. This week we welcome Elissa Cote, Director of Strategy and Business Development, Mallinckrodt Pharmaceuticals.
Elissa Cote is the Senior Vice President and Director of Strategy and Business Development at Mallinckrodt Pharmaceuticals. She is responsible for corporate strategy, licensing, management of mergers and acquisitions and alliances, and is a member of the management team of Mallinckrodt.
Ms. Cote has nearly 15 years of direct experience in the biopharmaceutical industry and an additional 10 years of strategic consulting and management experience. Ms. Cote has extensive expertise in commercial and commercial strategy, as well as therapeutic and disease strategy in several core therapeutic areas including CNS, autoimmunity / inflammation, gastrointestinal, respiratory, hepatology, regenerative medicine and rare orphan disease. Ms. Cote also has significant expertise in business development, global strategic marketing, new product pre-marketing / planning, business analysis and insights, and portfolio and product prioritization, in addition to experience in international markets, particularly in Europe, Japan and China.
Previously, Ms. Cote led the marketing and alliance management teams at Sucampo Pharmaceuticals until 2018, when Sucampo was acquired by Mallinckrodt where she then assumed the role of Senior Vice President, Head of Global Marketing and business development. Prior to joining Sucampo, Ms. Cote held positions of increasing responsibility at Histogenics Corporation and AstraZeneca. Prior to joining the Life Sciences industry, Ms. Cote spent over 10 years as a Strategy and Management Consultant at Accenture.
1. Please introduce yourself to our audience with feedback on your education, training and career.
My name is Elissa Cote and I have lived in Northern Virginia with my family since I moved here in 1998. I am actually considered a “transplant” because I grew up in Maryland until which I left for college in 1992. As most BioBuzz readers know, you are either a diehard Virginian or a diehard Marylander. So I guess I’m a real hybrid.
I attended a small liberal arts college, Union College, in upstate New York with the full intention of going to law school (I wanted to focus on a career in law school). medical malpractice). Instead, I ended up taking a whole different path in my senior year – I was hired by Anderson Consulting (now Accenture) in 1996 and was a strategy / management consultant for the first half of this year. my career. In my 30s, I made a career shift to pharma / biotech after having kids, and started with Medimmune in 2008 … and ~ 13 years later my pharmaceutical journey brought me here at Mallinckrodt Pharmaceuticals, where I have worked for over three years.
2. Introduce Mallinckrodt to our readers with a bit of history, places and vision.
Most people don’t know that Mallinckrodt is over 150 years old, with a very long history and a rich heritage. The company has actually formulated and supplied pharmaceuticals since the early 1920s.e Century. Mallinckrodt was founded in 1867 in St. Louis, Missouri as one of the first chemical manufacturing companies. The company has evolved into a global nuclear drug and pharmaceutical company, transitioning to radiopharmaceuticals at some point over the next several decades.
Mallinckrodt is now a global company made up of several wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceuticals, therapies and generics. The company’s specialty pharmaceutical businesses include autoimmune and rare diseases in specialty areas such as neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal intensive respiratory care therapies; analgesics and gastrointestinal products. The Specialty Generics business includes generic specialty drugs and active pharmaceutical ingredients. We report approximately $ 3 billion in sales and have over 3,000 employees worldwide.
3. You’ve been here for some time in the BioHealth Capital area with companies like MedImmune and Sucampo. How have you seen the region evolve into a bigger hub?
It has been quite remarkable over the past two decades to see firsthand how the Capital Region has changed and evolved into the burgeoning mecca of BioHealth. For a long time, biopharmaceutical companies had found good homes in typical American states and geographies such as New Jersey, New York, Massachusetts (Boston, Cambridge, Waltham), California (San Diego, San Francisco), PA (Philly ) and the North. Caroline. However, over the past decade, pharmacy, and biotechnology in particular, has really exploded in Maryland. I remember when I could only name and count the pharmaceutical / biotech companies I knew in the area on the one hand, maybe two if I was lucky.
Now, in 2021, it feels like a new pharmaceutical / biotech company or manufacturing plant / facility is starting, relocating or expanding to Maryland every month. Thus, the original vision for this field to become a biotechnology hub is in fact a real thing now. Growing up in Silver Spring, MD, I am delighted and proud that my home state is now considered one of the primary areas where pharmacy and biotechnology find a home. It is really quite impressive.
4. As Director of Strategy and Business Development at Mallinckrodt, what are you really excited and proud to be working on right now? Tell us about it.
Mallinckrodt embraces the development of its leaders and top talent. I have been fortunate enough to be one of the main beneficiaries of this culture and mentality over the past 3 years.
As our industry continues to change and evolve, so do pharmaceutical companies, and Mallinckrodt is no different. Being at the forefront as Mallinckrodt strives to adapt to change and other business challenges unique to our company has been an incredible learning experience. As Chief Strategy & BD Officer, I’m responsible for translating this into our business strategy and growth plans… which is challenging and at times intimidating, but also rewarding and empowering at the same time.
Frankly, I can’t imagine playing another role right now, and I’m grateful to the amazing colleagues, leaders and friends who have taught and supported me throughout my journey, such as my colleagues at Accenture (many of whom I am still close today) and longtime friends / colleagues at MedImmune (you know who you are the RIA team).
To answer your question directly, there is a specific development program in a rare orphan disease that I have supported and led over the past few years (in 2 different companies) that impacts me every day. The program is the only part of my job that makes me jump out of bed in the morning with the thought that I can somehow make a difference in the lives of patients; while at the same time it keeps me awake almost every night trying to figure out how to overcome the challenges we face as an industry grappling with the complicated conundrum of bringing orphan drugs to market rare … and above all, to patients.
5. If you could learn a skill in the world without trying (like in the matrix), which one would you choose and why?
I would choose to learn to fly. I’ve always been interested in aerodynamics and fascinated with how these giant pieces of metal can glide weightlessly (at least it would seem) through the air. My astonishment, curiosity and wonder on flight is so deep that I joke with my friends / family that I must have been a pilot in a previous life… not an airline pilot, but maybe an airline pilot. hunt or even an astronaut.
Maybe I’ll learn to fly (again?) In the next life, because frankly, this life is a little too busy.
Thank you Elissa Cote, Director of Strategy and Business Development, Mallinckrodt Pharmaceuticals for participating in the “5 Questions With BioBuzz” series and stay tuned for more interviews with others from across the BioHealth Capital region and beyond.
Andy has worked with BioBuzz for the past decade to help market the BioHealth Capital Region even before it goes by that name. His experience includes years at MedImmune supporting the organization of business operations before becoming a BioHealth Nomad working with various clients in operations, communications and strategic services.
- 5 questions with Elissa Cote, Director of Strategy and Business Development, Mallinckrodt Pharmaceuticals – May 25, 2021
- Commission appoints Amritha Jaishankar, Ph.D. as Executive Director, Maryland Stem Cell Research Fund (MSCRF) – May 18, 2021
- 5 questions with Raphaella Thorson, Head of R&D Learning Technologies, AstraZeneca – May 14, 2021
- 5 questions with Alia Poonawala, Managing Director, Hire Hopkins – May 7, 2021
- 5 questions with Caleb McKinney, Ph.D., MPS., Associate Dean, Georgetown University Biomedical Graduate Education – May 4, 2021